BRIEF published on 11/14/2024 at 19:05, 6 days 15 hours ago ABIONYX Pharma: Third quarter 2024 financial report Biotechnology Treasury Turnover Q3 2024 ABIONYX Pharma
PRESS RELEASE published on 11/14/2024 at 19:00, 6 days 15 hours ago Quarterly financial reporting / Third quarter financial report ABIONYX Pharma reports Q3 2024 revenue of €3.4m and cash position of €4.1m before IRIS Pharma's CIR receipt. General Meeting on November 28, 2024, at 2.00 pm CET Cash Position General Meeting Biotech Company ABIONYX Pharma Revenue Update
BRIEF published on 10/24/2024 at 19:35, 27 days 15 hours ago ABIONYX Pharma presents the results of the RACERS study ABIONYX Pharma CER-001 Brain Fog Kidney Week Neuroinflammation
PRESS RELEASE published on 10/24/2024 at 19:30, 27 days 15 hours ago Inside Information / Other news releases ABIONYX Pharma's RACERS study on CER-001 shows positive impact on cognitive impairment in brain-fog patients, presenting new clinical results at ASN 2024 Annual Meeting. Potential treatment for neuroinflammation ABIONYX Pharma CER-001 Brain-fog Neuroinflammation RACERS Study
BRIEF published on 10/21/2024 at 20:05, 30 days 14 hours ago ABIONYX Pharma receives positive EMA opinion for CER-001 ABIONYX Pharma CER-001 EMA AMM LCAT Deficiency
PRESS RELEASE published on 10/21/2024 at 20:00, 30 days 14 hours ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 2 months 29 days ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 2 months 29 days ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 4 months 20 days ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
PRESS RELEASE published on 07/01/2024 at 09:22, 4 months 20 days ago Inside Information / Other news releases ABIONYX successfully completes a capital increase of c.€3.4 million through the issuance of shares with warrants. The fundraising aims to strengthen the company's cash position for its development in sepsis and the United States Fundraising Capital Increase Sepsis ABIONYX Shares With Warrants
Published on 11/21/2024 at 10:03, 43 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 46 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 1 hour 46 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 10 hours 11 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 10 hours 21 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 10:30, 16 minutes ago MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 10:04, 41 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:02, 44 minutes ago Supervisory Board appoints Carsten Schmitt as new CFO
Published on 11/21/2024 at 10:00, 46 minutes ago Nabaltec AG continues solid earnings performance in third quarter of 2024
Published on 11/21/2024 at 10:00, 46 minutes ago Deutsche Beteiligungs AG: Successful final closing of DBAG ECF IV
Published on 11/21/2024 at 06:58, 3 hours 48 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 15 hours 26 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 17 hours 1 minute ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 17 hours 1 minute ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 3 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
